JNJ-88549968

N/A

Report date: 2026/04/20 20:01:59
First In Class

Base Information

Drug NameJNJ-88549968
Drug Alias NameJNJ-88549968
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCalreticulin modulatorsT lymphocytes stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsCalreticulin
Therapy Area/IndicationsMyeloproliferative DisordersHematologic DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdCilag AgJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsMyeloproliferative DisordersHematologic DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A